These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31567279)

  • 1. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis.
    Xu ML; Gabali A; Hsi ED; Fedoriw Y; Vij K; Salama ME; Ramchandren R; O'Malley D; Wick MR; Battistella M; Gru AA
    Am J Surg Pathol; 2020 Feb; 44(2):e1-e14. PubMed ID: 31567279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
    Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
    Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
    Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
    Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pay attention to the detection and evaluation of CD30 in pathological diagnosis of lymphoma].
    Zhang ZH
    Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):287-289. PubMed ID: 35359037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
    Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
    Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment.
    Koens L; van de Ven PM; Hijmering NJ; Kersten MJ; Diepstra A; Chamuleau M; de Jong D
    Histopathology; 2018 Sep; 73(3):473-482. PubMed ID: 29758590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.
    Gopal AK; Bartlett NL; Forero-Torres A; Younes A; Chen R; Friedberg JW; Matous JV; Shustov AR; Smith SE; Zain J; O'Meara MM; Fanale MA
    Leuk Lymphoma; 2014 Oct; 55(10):2328-34. PubMed ID: 24359243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
    Gru AA; Lim MS; Dogan A; Horwitz SM; Delabie J; Fu K; Peker D; Reddy VVB; Xu ML; Vij K; Slack GW; Miranda RN; Jagadeesh D; Lisano JM; Hsi ED; Torlakovic E
    Arch Pathol Lab Med; 2023 Jan; 147(1):79-86. PubMed ID: 35472771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Pierce JM; Mehta A
    Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 is a potential therapeutic target in malignant mesothelioma.
    Dabir S; Kresak A; Yang M; Fu P; Wildey G; Dowlati A
    Mol Cancer Ther; 2015 Mar; 14(3):740-6. PubMed ID: 25589494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
    Sharman JP; Wheler JJ; Einhorn L; Dowlati A; Shapiro GI; Hilton J; Burke JM; Siddiqi T; Whiting N; Jalal SI
    Invest New Drugs; 2019 Aug; 37(4):738-747. PubMed ID: 30993587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.